The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 21, 2023

Filed:

Sep. 14, 2017
Applicants:

Agency for Science, Technology and Research, Singapore, SG;

National University of Singapore, Singapore, SG;

Inventors:

Walter Hunziker, Singapore, SG;

Jianliang Xu, Singapore, SG;

Jiong-Wei Wang, Singapore, SG;

P. Jaya Kausalya, Singapore, SG;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 35/761 (2015.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61P 9/10 (2006.01); A61K 31/713 (2006.01); A61K 31/7088 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/713 (2013.01); A61K 35/761 (2013.01); A61K 38/1709 (2013.01); A61K 38/1825 (2013.01); A61K 38/1866 (2013.01); A61K 38/1883 (2013.01); A61P 9/10 (2018.01); A61K 31/7088 (2013.01); A61K 38/1808 (2013.01); A61K 38/1841 (2013.01); C12N 15/1138 (2013.01); C12N 2310/11 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/341 (2013.01); C12N 2310/531 (2013.01);
Abstract

The invention is a method for treating a heart disease, in particular acute myocardial infarction (AMI) in a subject comprising the step of administering to the subject a Tjp1 inhibitor, wherein administration of said Tjp1 inhibitor promotes cardiomyocyte proliferation. The invention further includes use of Tjp1 inhibitor in the manufacture of a medicament for a heart disease, a patch, and a nucleic acid encoding a Tjp1 inhibitor. In a particular embodiment, the Tjp1 inhibitor is a nucleic acid, i.e. an siRNA or shRNA of Tjp1. The invention also includes administration of said Tjp1 inhibitor in combination with Neuregulin-1 (NRG1), Fibroblast growth factor (FGF), Vascular endothelial growth factor (VEGF) or Follistatin-like 1 (Fst1) and wherein said inhibitor is delivered in an adeno-associated virus of serotype 9 (AAV 9).


Find Patent Forward Citations

Loading…